U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16ClNO2S.C6H6O3S
Molecular Weight 479.997
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOPIDOGREL BESYLATE

SMILES

OS(=O)(=O)C1=CC=CC=C1.COC(=O)[C@@H](N2CCC3=C(C2)C=CS3)C4=CC=CC=C4Cl

InChI

InChIKey=CUZIJKLLBDXNFV-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.C6H6O3S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;7-10(8,9)6-4-2-1-3-5-6/h2-5,7,9,15H,6,8,10H2,1H3;1-5H,(H,7,8,9)/t15-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C16H16ClNO2S
Molecular Weight 321.822
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C6H6O3S
Molecular Weight 158.175
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Preventing
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

1997
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.521 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
15800 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4600 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2520 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1500 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.09 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
0.767 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
50600 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
9890 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7440 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
3130 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.4 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.9 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.4 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
8.5 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, unknown
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
Health Status: healthy
Age Group: 20-45 years
Sex: M
Sources:
Other AEs: Uric acid abnormal...
Other AEs:
Uric acid abnormal (5 patients)
Sources:
1650 mg single, oral
Overdose
Dose: 1650 mg
Route: oral
Route: single
Dose: 1650 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
Disc. AE: Transaminases increased, Fever...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Fever (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Uric acid abnormal 5 patients
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
Health Status: healthy
Age Group: 20-45 years
Sex: M
Sources:
Fever 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
Transaminases increased 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
Health Status: unhealthy
Age Group: 59 years
Sex: F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
yes [IC50 0.307 uM]
yes [IC50 6.25 uM]
yes [Ki 28 uM]
yes
yes
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
likely
no
no
no
no
no
no
yes [Km 181 uM]
yes [Km 19 uM]
yes [Km 20.9 uM]
yes [Km 5.61 uM]
yes
yes
yes
yes
yes
yes
PubMed

PubMed

TitleDatePubMed
Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers.
1998
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.
1999 Aug
Current oral antiplatelet agents to prevent atherothrombosis.
2001
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
2001
Atherothrombosis: a major health burden.
2001
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
2001 Apr
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
2001 Apr
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke.
2001 Apr
Antithrombotic drugs for secondary stroke prophylaxis.
2001 Apr
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease.
2001 Apr
[Acute heart attacks. Prognosis can be further improved].
2001 Apr 5
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
2001 Aug 18
Severe hypersensitivity associated with clopidogrel.
2001 Aug 21
Newer antiplatelet therapies in stroke prevention.
2001 Feb
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists.
2001 Feb
Antithrombotic and thrombolytic therapy for ischemic stroke.
2001 Feb
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement.
2001 Feb 1
Fatal aplastic anaemia associated with clopidogrel.
2001 Feb 10
[Update on the treatment with platelet antiaggregation agents].
2001 Jan
[Clopidogrel? Known or known?].
2001 Jan
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
2001 Jan 23
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting.
2001 Jan 25
Clopidogrel (Plavix): hematological reactions.
2001 Jan 9
Multiple intracranial aneurysms as delayed complications of an atrial myxoma: case report.
2001 Jul
Diffuse alveolar hemorrhage after clopidogrel use.
2001 Jul
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
2001 Jul 31
[Toxic skin reaction to clopidogrel].
2001 Jun
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
2001 Jun
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
2001 Jun 15
[Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification].
2001 Mar
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
2001 Mar
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation.
2001 Mar
Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel.
2001 Mar
[Therapeutic aspects of cerebral ischemia].
2001 Mar 10
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
2001 May
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
2001 May
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
2001 May 1
P2y(12), a new platelet ADP receptor, target of clopidogrel.
2001 May 4
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
2001 Oct 15
Coronary stent thrombosis: insights from the porcine coronary stent model.
2001 Sep
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
2001 Sep
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
2001 Sep
Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment.
2001 Sep
Endovascular brachytherapy for prophylaxis against restenosis after long-segment femoropopliteal placement of stents: initial results.
2001 Sep
Patents

Sample Use Guides

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease The recommended daily dose of is 75 mg once daily.
Route of Administration: Oral
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:02:04 GMT 2025
Edited
by admin
on Mon Mar 31 19:02:04 GMT 2025
Record UNII
BL9VGG8BHW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLOPIDOGREL BESILATE
EMA EPAR  
Preferred Name English
CLOPIDOGREL BESYLATE
WHO-DD  
Common Name English
CLOPIDOGREL APOTEX
Brand Name English
CLOPIDOGREL BENZENESULFONIC ACID SALT
Common Name English
CLOPIDOGREL ACINO PHARMA GMBH
Brand Name English
CLOPIDOGREL ACINO PHARMA
Brand Name English
CLOPIDOGREL RATIOPHARM GMBH
Brand Name English
CLOPIDOGREL HEXAL
Brand Name English
CLOPIDOGREL ACINO
Brand Name English
GREPID
Brand Name English
CLOPIDOGREL SANDOZ
Brand Name English
CLOPIDOGREL 1A-PHARMA
Brand Name English
Clopidogrel Besylate [WHO-DD]
Common Name English
CLOPIDOGREL BENZENESULFONATE
Common Name English
CLOPIDOGREL BESILATE [EP MONOGRAPH]
Common Name English
THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-6,7-DIHYDRO-, METHYL ESTER, (.ALPHA.S)-, BENZENESULFONATE
Common Name English
CLOPIDOGREL-RATIOPHARM
Brand Name English
CLOPIDOGREL BESILATE [EMA EPAR]
Common Name English
(S)-METHYL-2-(2-CHLOROPHENYL)-2-(6,7-DIHYDROTHIENO(3,2-C)PYRIDIN-5(4H)-YL)ACETATE METHANESULFONATE
Systematic Name English
THIENO(3,2-C)PYRIDINE-5(4H)-ACETIC ACID, .ALPHA.-(2-CHLOROPHENYL)-6,7-DIHYDRO-, METHYL ESTER, (.ALPHA.S)-, BENZENESULFONATE (1:1)
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS CLOPIDOGRAL HEXAL (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL HEXAL (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL RATIOPHARM (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO PHARMA (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL SANDOZ (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL 1A-PHARMA (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL SANDOZ (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL 1A PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS GREPID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL HEXAL (WITHDRAWN:
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS GREPID (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL APOTEX (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL RATIOPHARM (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL HEXAL (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL APOTEX (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL HEXAL (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL 1A PHARMA (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL SANDOZ (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS GREPID (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL 1A PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO (AUTHORIZED: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: STROKE)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
EMA ASSESSMENT REPORTS CLOPIDOGREL APOTEX (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
Code System Code Type Description
CAS
744256-69-7
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
DRUG BANK
DBSALT002628
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
EVMPD
SUB30714
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
FDA UNII
BL9VGG8BHW
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
SMS_ID
100000115443
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
PUBCHEM
9847991
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
EPA CompTox
DTXSID30225441
Created by admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY